AR126954A1 - METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS - Google Patents

METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS

Info

Publication number
AR126954A1
AR126954A1 ARP220102366A ARP220102366A AR126954A1 AR 126954 A1 AR126954 A1 AR 126954A1 AR P220102366 A ARP220102366 A AR P220102366A AR P220102366 A ARP220102366 A AR P220102366A AR 126954 A1 AR126954 A1 AR 126954A1
Authority
AR
Argentina
Prior art keywords
methods
receptor antagonists
cgrp receptor
treating psoriasis
snhc
Prior art date
Application number
ARP220102366A
Other languages
Spanish (es)
Inventor
Robert Croop
Daniel Franjic
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of AR126954A1 publication Critical patent/AR126954A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

Se proporcionan métodos para tratar la psoriasis con uno o más antagonistas de receptores de CGRP y/o sus composiciones farmacéuticas. Tales métodos son útiles para tratar, mejorar, aliviar, proporcionar profilaxis o prevención, detener la progresión y/o reducir el riesgo de psoriasis en un sujeto mamífero, tal como un humano. En particular, los antagonistas del receptor de CGRP tales como los de fórmula (1), fórmula (2) y/o fórmula (1) son útiles en métodos para tratar la psoriasis en un sujeto que lo necesita, donde de un modo general A es CH; D es O, NCN o NSO₂alquiloC₁₋₃; E es N, CE o C; G, J y E juntos forman Aˣ; Aˣ es un heterociclo fusionado que tiene dos anillos fusionados con 5 a 7 miembros en cada uno de dichos anillos; m, n y p son cada uno 1; Q’ es (Sʸ)ₛR³; Q es un enlace, C(O), C(O)O o Q es Q’ o Q’’; Q’’ es NH(Sʸ)ₛR³, NHC(O(Sʸ)ₛR³, NHC(O)O(Sʸ)ₛR³, NHC(O)NH(Sʸ)ₛR³, O(Sʸ)ₛR³, (Sʸ)₃NHR³, (Sʸ)ₛNHC(O)R³, (Sʸ)ₛNHC(O)OR³, (Sʸ)ₛNHC(O)NHR³ o (Sʸ)ₛOR³; U es CH₂ o NH; V es -N(R¹)(R²) o OR⁴; y en donde de un modo más preciso y detallado se describen en el presente documento.Methods are provided for treating psoriasis with one or more CGRP receptor antagonists and/or their pharmaceutical compositions. Such methods are useful for treating, ameliorating, alleviating, providing prophylaxis or prevention, arresting the progression and/or reducing the risk of psoriasis in a mammalian subject, such as a human. In particular, CGRP receptor antagonists such as those of formula (1), formula (2) and/or formula (1) are useful in methods of treating psoriasis in a subject in need thereof, where generally A is CH; D is O, NCN or NSO₂C₁₋₃alkyl; E is N, CE or C; G, J and E together form Aˣ; Aˣ is a fused heterocycle having two fused rings with 5 to 7 members in each of said rings; m, n and p are each 1; Q is (Sʸ)ₛR³; Q is a bond, C(O), C(O)O or Q is Q or Q; Q is NH(Sʸ)ₛR³, NHC(O(Sʸ)ₛR³, NHC(O)O(Sʸ)ₛR³, NHC(O)NH(Sʸ)ₛR³, O(Sʸ)ₛR³, (Sʸ)₃NHR³, ( Sʸ)ₛNHC(O)R³, (Sʸ)ₛNHC(O)OR³, (Sʸ)ₛNHC(O)NHR³ or (Sʸ)ₛOR³; U is CH₂ or NH; V is -N(R¹)(R²) or OR⁴; and where they are described in a more precise and detailed way in this document.

ARP220102366A 2021-09-02 2022-09-01 METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS AR126954A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163240064P 2021-09-02 2021-09-02

Publications (1)

Publication Number Publication Date
AR126954A1 true AR126954A1 (en) 2023-12-06

Family

ID=85412863

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102366A AR126954A1 (en) 2021-09-02 2022-09-01 METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS

Country Status (2)

Country Link
AR (1) AR126954A1 (en)
WO (1) WO2023034466A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE60326370D1 (en) * 2002-08-12 2009-04-09 Actavis Group Hf USE OF CGRP ANTAGONIST COMPOUNDS FOR THE TREATMENT OF PSORIASIS
RS20060382A (en) * 2003-12-05 2008-09-29 Bristol-Myers Squibb Company, Calcitonin gene related peptide receptor antagonists
LT3254681T (en) * 2012-02-27 2019-09-25 Bristol-Myers Squibb Company N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
GB201519196D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
SG11202106721VA (en) * 2019-01-20 2021-07-29 Biohaven Pharm Holding Co Ltd Cgrp antagonists for treating migraine breakthrough

Also Published As

Publication number Publication date
WO2023034466A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
AR115885A1 (en) COMPOUNDS DERIVED FROM 1H-PYRAZOLO [4,3-D] PYRIMIDINE AS AGONISTS OF THE TOLL TYPE 7 RECEPTOR (TLR7) AND THEIR USE IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT
AR109788A1 (en) BENZO COMPOUNDS [B] THIOPHEN AS STING AGONISTS
AR112693A1 (en) 3-PHENYL-5-TRIFLUOROMETILISOXAZOLIN-5-CARBOXAMIDES OF CYCLOPENTILCARBOXYLIC ACIDS AND ESTERS WITH HERBICIDAL EFFECT
AR010067A1 (en) 5-RING HETERO CYCLES AS INHIBITORS OF THE ACCESSION OF LEUKOCYTES AND VLA-4 ANTAGONISTS
AR112098A1 (en) 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES OF TETRAHYDRO- AND DIHYDROFURANCARBOXAMIDE WITH HERBICIDE EFFECT
AR010065A1 (en) HETEROCYCLIC COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF USEFUL PHARMACS AS INHIBITORS OF THE ACCESSION OF LEUKOCYTES AND ANTAGONISTS OF THE VLA-4
AR099367A1 (en) INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON
ES179305A1 (en) A PROCEDURE FOR PREPARING LIQUID POLYSYLOXANES
ECSP19029835A (en) CYCLIC TYROSINE PEPTIDE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE RECEPTORS AND
AR114828A1 (en) PTERIDINONE COMPOUNDS AND THEIR USES
AR095279A1 (en) N- (4- (AZAINDAZOL-6-IL) -PENYL) -SULPHONAMIDS AND ITS USE AS PHARMACEUTICAL PRODUCTS
PE20180119A1 (en) TRICYCLIC SULPHONES AS MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORGAMMA)
AR098776A1 (en) ISOCROMENE DERIVATIVES AS INHIBITORS OF PHOSFOINOSITIDO-3 KINASES
AR092670A1 (en) DERIVATIVES OF QUINAZOLINONA
AR116114A1 (en) HETEROCYCLIC AMIDAS BETWEEN 5 AND 7 MEMBERS AS JAK INHIBITORS
AR094553A1 (en) FORMS OF OXADIAZOLPIRAZINA
AR103232A1 (en) TGFbR ANTAGONISTS
AR114369A1 (en) CYCLIC DINUCLEOTIDES AS ANTINEOPLASTIC AGENTS
AR113790A1 (en) SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND THEIR USE
AR111494A1 (en) ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT
AR126954A1 (en) METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS
AR114496A1 (en) ANTIPROLIFERATION COMPOUNDS AND USES OF THEM
AR102258A1 (en) QUINOLINE AND QUINAZOLINE COMPOUNDS
CL2018000231A1 (en) Adamantilurea analogs as soluble epoxide hydrolase inhibitors
UY38304A (en) CYCLIC DINUCLEOTIDES AS STING AGONISTS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM

Legal Events

Date Code Title Description
FB Suspension of granting procedure